Content continues after advertisement

Research Note: Monoclonal Antibodies for Treatment of Immunosuppressive Cancer in Dogs


|March 2019

Sign in to Print/View PDF

Immunotherapy, particularly with regard to cancer treatment, is currently an area of focus in research, but little is known about the function of immune inhibitor molecules in veterinary medicine. In this study, monoclonal antibodies against 2 immune inhibitory receptors (ie, canine programmed death-1 [cPD-1], canine programmed death ligand-1 [cPD-L1]) were identified. These antibodies bound to cells overexpressing cPD-1 and cPD-L1, effectively blocking binding between cPD-1 and cPD-L1. Each antibody was found to have a different blocking ability and a specific functional blockade. These newly generated antibodies may provide a novel approach to treatment of dogs with immunosuppressive cancers.


For global readers, a calculator to convert laboratory values, dosages, and other measurements to SI units can be found here.

All Clinician's Brief content is reviewed for accuracy at the time of publication. Previously published content may not reflect recent developments in research and practice.

Material from Clinician's Brief may not be reproduced, distributed, or used in whole or in part without prior permission of Educational Concepts, LLC. For questions or inquiries please contact us.


Clinician's Brief:
The Podcast
Listen as host Alyssa Watson, DVM, talks with the authors of your favorite Clinician’s Brief articles. Dig deeper and explore the conversations behind the content here.
Clinician's Brief provides relevant diagnostic and treatment information for small animal practitioners. It has been ranked the #1 most essential publication by small animal veterinarians for 9 years.*

*2007-2017 PERQ and Essential Media Studies

© 2023 Educational Concepts, L.L.C. dba Brief Media ™ All Rights Reserved. Terms & Conditions | DMCA Copyright | Privacy Policy | Acceptable Use Policy